- Home
- INTS vs VERB Comparison
INTS vs VERB Comparison
Compare INTS & VERB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- VERB
- Stock Information
- Founded
- INTS 2012
- VERB 2014
- Country
- INTS United States
- VERB United States
- Employees
- INTS N/A
- VERB N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- VERB Other Consumer Services
- Sector
- INTS Health Care
- VERB Consumer Discretionary
- Exchange
- INTS Nasdaq
- VERB Nasdaq
- Market Cap
- INTS 8.4M
- VERB 9.6M
- IPO Year
- INTS 2023
- VERB N/A
- Fundamental
- Price
- INTS $0.28
- VERB $9.74
- Analyst Decision
- INTS Strong Buy
- VERB Strong Buy
- Analyst Count
- INTS 2
- VERB 1
- Target Price
- INTS $6.75
- VERB $62.00
- AVG Volume (30 Days)
- INTS 5.7M
- VERB 39.4K
- Earning Date
- INTS 08-11-2025
- VERB 08-13-2025
- Dividend Yield
- INTS N/A
- VERB N/A
- EPS Growth
- INTS N/A
- VERB N/A
- EPS
- INTS N/A
- VERB N/A
- Revenue
- INTS N/A
- VERB $2,193,000.00
- Revenue This Year
- INTS N/A
- VERB $526.82
- Revenue Next Year
- INTS N/A
- VERB $45.45
- P/E Ratio
- INTS N/A
- VERB N/A
- Revenue Growth
- INTS N/A
- VERB 3125.00
- 52 Week Low
- INTS $0.26
- VERB $3.81
- 52 Week High
- INTS $4.94
- VERB $20.60
- Technical
- Relative Strength Index (RSI)
- INTS 35.87
- VERB 58.92
- Support Level
- INTS $0.32
- VERB $8.00
- Resistance Level
- INTS $0.36
- VERB $11.87
- Average True Range (ATR)
- INTS 0.03
- VERB 0.86
- MACD
- INTS 0.00
- VERB 0.09
- Stochastic Oscillator
- INTS 1.88
- VERB 44.96
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About VERB Verb Technology Company Inc.
Verb Technology Co Inc leader in interactive video-based sales applications, transforms how businesses attract and engage customers. VERB's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.